SAREPTA THERAPEUTICS INC (SRPT) Stock News
NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD
SRPT Latest News, Press Relases and Analysis
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such...
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities...
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Can Solid Biosciences Challenge Sarepta in the DMD Market?
Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.
Mentions: SLDB
3 Reasons to Avoid SRPT and 1 Stock to Buy Instead
The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have lost 56.6% of their capital. This may have investors wondering how to approach the situation.
Mentions: NET
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. Read on to learn more about four biotechs with price targets that imply significant upsides (based on prices as of Apr. 3) of between 50% and 543% in the next year. Of the pure-play gene editing specialists on the market, CRISPR Therapeutics (NASDAQ: CRSP) is one of the more prominent.
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops
H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise.
Sarepta Therapeutics Provides Update on ELEVIDYS
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
The holds are temporary while the teenager's death is under investigation.
Sarepta price target lowered to $179 from $210 at BofA
BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the departure of Peter Marks from the FDA’s Center for Biologics Evaluation and Research, the firm is lowering its Elevidys estimates by about 20% out of an abundance of caution. While it is early, and its conversation with Sarepta today indicates they don’t expect an immediate impact, BofA thinks the open seat introduces additional uncertainty in addition to the r
Sands Capital Select Growth Fund Closed Lam Research Corporation (LRCX) on Valuation Concerns
Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S. companies that are leading the way in crucial areas of positive structural transformation within the economy. The fund returned 8.8% (net) in the fourth […]
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced technologies. Over the weekend, Dr. Peter Marks, who headed the FDA's Center for Biologics Evaluation and Research, as well as its vaccine division, resigned in protest.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such...
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.